Table 2.
Clinical findings from the study groups
| Clinical features | MAS, N = 39 | Non-MAS, N = 375 | p value |
|---|---|---|---|
| Skin rash, N (%) | 25 (64.1) | 230 (61.3) | 0.74 |
| Splenomegaly, N (%) | 11 (28.2) | 126 (33.6) | 0.49 |
| Liver involvement, N (%) | 19 (48.7) | 123 (32.8) | 0.047 |
| Hepatomegaly, N (%) | 16 (41) | 86 (22.9) | 0.02 |
| Lymphadenopathy, N (%) | 25 (64.1) | 182 (48.5) | 0.065 |
| Pneumonia, N (%) | 4 (10.3) | 17 (4.5) | 0.12 |
| Serositis (any site), N (%) | 13 (33.3) | 102 (27.2) | 0.42 |
| Pleuritis, N (%) | 8 (20.5) | 50 (13.3) | 0.22 |
| Pericarditis, N (%) | 4 (10.3) | 50 (13.3) | 0.59 |
| Peritonitis, N (%) | 1 (2.6) | 3 (0.8) | 0.28 |
| Thoracic pain, N (%) | 4 (10.3) | 37 (9.9) | 0.94 |
| Abdominal pain, N (%) | 10 (25.6) | 46 (12.3) | 0.06 |
| Arthritis, N (%) | 21 (53.8) | 216 (57.6) | 0.65 |
| Myalgia, N (%) | 23 (59) | 186 (49.6) | 0.27 |
| Eye involvement, N (%) | 5 (12.8) | 15 (4) | 0.02 |
| Scleritis, N (%) | 3 (7.7) | 0 (0) | < 0.001 |
| Conjunctivitis, N (%) | 2 (5.1) | 11 (3) | 0.46 |
| Kidney, N (%) | 2 (5.1) | 7 (1.9) | 0.18 |
| Orchitis, N (%) | 0/0 (0) | 3 (0.8) | 0.58 |
| Neurologic, N (%) | 2 (5.1) | 9 (2.4) | 0.31 |
| ARDS, N (%) | 4 (10.3) | 1 (0.3) | < 0.001 |
| Fulminant hepatic failure, N (%) | 2 (5.1) | 1 (0.3) | 0.001 |
| Highest BT, °C; median (IQR) | 40 (0.65) | 39.5 (1.0) | 0.02 |
| Highest BT | |||
| ≥ 39 °C, N (%) | 38 (97.4) | 317 (84.5) | 0.03 |
p values were obtained with Student’s t test for quantitative data and Chi-square test or Fisher exact test (according to the sample size and expected frequencies) for qualitative data
ARDS acute respiratory distress syndrome, BT body temperature, IQR interquartile range, MAS macrophage activation syndrome